-
目前对DTC(包括乳头状癌与滤泡状癌)公认的治疗方法包括外科手术、术后的131I治疗以及后续的甲状腺激素抑制治疗[1]。大多数患者经过上述治疗能获得长期无病生存。健康相关生存质量(health-related quality of life,HRQOL)是一个反映患者对自己身体、心理以及社会功能主观感受的多维概念。在癌症的长期管理过程中,患者的生存质量越来越受到重视[2],因此,癌症治疗的最终目标不仅仅是提高患者的生存率,同时提高生存质量也显得至关重要。目前关于131I治疗对甲状腺癌患者生存质量影响的研究较少且结果不一致。有研究结果表明,131I治疗会降低DTC患者的生存质量[3]。而实际上131I治疗与否以及治疗剂量都是依据患者病情而定的,且131I治疗前后患者的生存质量受很多因素影响,因此,单纯地比较治疗前后患者的生存质量得分或比较治疗者与未治疗者的生存质量得分并不能准确反映131I治疗对患者生存质量的影响。
欧洲癌症研究与治疗组织(European Organization for Research and Treatment of Cancer,EORTC)开发的生存质量核心量表30(quality of life questionnaire-core 30,QLQ-C30)(简称EORTC QLQ-C30)是癌症患者生存质量核心量表,广泛应用于手术或治疗方案的选择以及药物疗效、不良反应、干预因素的评价。我们采用该量表分析甲状腺乳头状癌(papillary thyroid carcinoma,PTC)患者HRQOL的基本情况,通过比较分期相同但接受的治疗方法不同的患者在不同时间点的得分来探讨131I治疗是否会影响PTC患者的HRQOL。
-
由表1可知,患者组与对照组的年龄和BMI、术前TSH和Tg水平的差异均无统计学意义(均P>0.05);患者组术后6个月的TSH和Tg水平均明显低于对照组,且差异均有统计学意义(均P<0.01)。
组别 年龄( ±s,岁)$\bar x $ BMI( ±s,kg/m2)$ \bar x$ TSH[M(P75−P25),mIU/L] Tg[M(P75−P25),ng/mL] 术前 术后6个月 术前 术后6个月 PTC患者组(n=356) 41.00±9.64 26.00±3.91 2.68(1.86) 0.12(0.39) 14.58(27.21) 0.05(0.18) 对照组(n=400) 41.70±9.38 26.46±3.94 1.94(1.81) 1.94(1.81) 16.14(27.02) 16.14(27.02) Z值 −0.510 −0.050 −0.672 −21.33 −0.473 −23.25 P值 0.552 0.938 0.372 <0.01 0.636 <0.01 注:PTC为甲状腺乳头状癌;BMI为体重指数;TSH为促甲状腺激素;Tg为甲状腺球蛋白 表 1 PTC患者组与对照组的一般资料、TSH和Tg的比较
Table 1. Comparison of general data, thyroid-stimulating hormone and thyroglobulin levels between papillary thyroid cacinoma patients and controls
由表2可知,患者组术前GQOL得分明显低于对照组,除了身体功能以外的其他功能领域的得分均低于对照组,除了疼痛以外的其他症状领域的得分均高于对照组,且差异均有统计学意义(均P<0.05);术后6个月,患者组GQOL得分与术前相比有明显提升,除了身体功能、认知功能、社会功能以外的其他功能领域的得分均比术前升高,除了乏力、疼痛、气短以外的其他症状领域的得分均比术前降低,且差异均有统计学意义(均P<0.05)。
领域 PTC患者组(n=356) 对照组(n=400) 术前 术后6个月 总体生活质量 59.11±21.12a 73.88±18.04ab 83.08±14.62 功能领域 身体功能 88.91±9.44 89.19±9.25 89.40±9.06 角色功能 80.24±14.07a 82.96±15.14ab 89.58±15.67 情绪功能 74.74±14.55a 78.82±12.88ab 91.42±11.93 认知功能 82.87±15.70a 80.62±16.11a 88.37±14.20 社会功能 85.07±16.41a 83.61±17.08a 91.21±19.14 症状领域 乏力 24.34±21.84a 17.10±15.23a 7.97±10.87 恶心或呕吐 7.30±10.59a 2.29±7.61ab 2.71±6.58 疼痛 8.01±11.81 6.13±8.78 7.33±11.86 气短 13.86±17.88a 16.85±18.10ab 7.75±15.03 失眠 34.64±27.57a 23.69±25.55ab 14.50±19.74 食欲下降 20.41±21.24a 12.45±20.40b 9.58±15.09 便秘 16.01±19.42a 6.65±14.66b 6.33±13.08 腹泻 10.39±16.23a 6.93±15.46b 7.17±13.69 经济困难 15.45±20.34a 11.42±17.86b 11.08±17.22 注:a表示与对照组比较,差异均有统计学意义(Z=−7.806~−2.236,均P<0.05);b表示与术前比较,差异均有统计学意义(Z=−5.790~−2.876,均P<0.05)。PTC为甲状腺乳头状癌;EORTC QLQ-C30为欧洲癌症研究与治疗组织开发的生存质量核心量表30 表 2 PTC患者组术前、术后6个月与对照组的EORTC QLQ- C30 得分的比较(
±s)$\bar x$ Table 2. EORTC QLQ-C30 scores between papillary thyroid cacinoma patients and controls before the operation and at 6 months after the operation (
±s)$\bar x$ -
由表3可知,131I治疗组与未治疗组患者的年龄和BMI、术前及术后(3、6个月)的TSH和Tg水平的差异均无统计学意义(均P>0.05),术后1个月131I 治疗组的TSH和Tg水平明显高于未治疗组,且差异均有统计学意义(均P<0.01)。
组别 年龄
( ±s,岁)$\bar x $ BMI
( ±s,kg/m2)$\bar x $ TSH[M(P75−P25),mIU/L] Tg[M(P75−P25),ng/mL] 术前 术后1个月 术后3个月 术后6个月 术前 术后1个月 术后3个月 术后6个月 131I治疗组(n=205) 41.27±9.54 26.48±3.90 2.68(1.74) 107.97(34.50) 0.13(0.27) 0.11(0.35) 13.63(27.19) 1.83(6.17) 0.08(0.24) 0.04(0.18) 未治疗组(n=151) 41.50±9.77 26.47±3.93 2.76(1.92) 0.27(0.84) 0.17(0.43) 0.14(0.13) 18.47(25.14) 0.05(0.17) 0.09(0.27) 0.07(0.18) Z值 −0.172 −0.402 −0.107 −6.159 −1.117 −0.543 −0.662 −10.061 −1.332 −1.117 P值 0.863 0.688 0.903 <0.01 0.264 0.583 0.547 <0.01 0.183 0.325 注:PTC为甲状腺乳头状癌;BMI为体重指数;TSH为促甲状腺激素;Tg为甲状腺球蛋白 表 3 2组PTC患者的一般资料、TSH和Tg的比较
Table 3. Comparison of general data, thyroid-stimulating hormone and thyroglobulin levels between 131I treatment and non-131I treatment papillary thyroid cacinoma patients
由表4可知,131I治疗组与未治疗组PTC患者术前GQOL得分及其他所有领域的得分的差异均无统计学意义(Z=−0.876~−0.001,均P>0.05);术后1个月,131I治疗组GQOL得分低于未治疗组,功能领域的得分均低于未治疗组,除了疼痛、腹泻、经济困难以外的其他症状领域的得分均高于未治疗组,且差异均有统计学意义(均P<0.05);术后3个月,131I治疗组GQOL得分仍低于未治疗组,但131I治疗组功能领域仅有角色功能、情绪功能、社会功能的得分低于未治疗组,症状领域仅有失眠、食欲下降的得分高于未治疗组,且差异均有统计学意义(均P<0.05);术后6个月,131I治疗组与未治疗组的GQOL得分及其他所有领域的得分的差异均无统计学意义(Z=−2.550~−0.008,均P>0.05)。
组别 术前 术后1个月 术后3个月 术后6个月 131I治疗组(n=205) 总体生活质量 58.94±21.29 50.57±17.72 64.43±32.12 73.86±18.26 功能领域 身体功能 88.72±9.40 75.42±13.59 87.25±11.04 89.14±9.33 角色功能 80.16±14.14 70.16±23.14 77.32±17.93 82.76±15.12 情绪功能 74.92±14.52 68.94±16.12 73.54±15.57 77.52±13.29 认知功能 82.93±15.38 72.36±18.33 77.56±19.49 81.22±15.99 社会功能 85.61±16.22 73.09±22.89 78.86±21.66 83.90±16.98 症状领域 乏力 23.74±21.48 31.33±19.05 27.53±16.59 17.45±15.64 恶心或呕吐 7.16±10.56 9.43±12.23 2.60±6.95 2.28±7.56 疼痛 7.89±11.82 18.13±16.15 16.91±16.00 5.93±8.63 气短 14.15±17.74 26.01±21.98 21.46±20.69 16.42±17.92 失眠 34.63±27.32 33.33±29.08 29.59±26.79 22.93±25.72 食欲下降 20.32±20.92 18.70±23.80 17.56±22.94 12.52±20.83 便秘 16.26±19.65 22.44±26.66 11.06±19.40 6.83±14.98 腹泻 10.24±16.07 5.69±14.17 6.18±14.15 6.83±15.34 经济困难 14.96±20.92 21.14±25.46 15.61±20.70 12.03±18.52 未治疗组(n=151) 总体生活质量 59.33±20.95 55.74±18.82 a 72.68±17.29 a 73.57±18.01 功能领域 身体功能 89.18±9.51 82.56±15.78 a 88.30±10.55 89.27±9.14 角色功能 80.35±14.02 78.48±19.80 a 81.46±17.32 a 83.56±15.03 情绪功能 74.50±14.63 75.11±15.61 a 79.86±15.36 a 80.08±12.69 认知功能 82.78±15.57 78.92±18.67 a 77.37±19.50 79.80±16.23 社会功能 84.33±16.69 79.58±22.22 a 84.16±17.48 a 83.11±17.15 症状领域 乏力 25.16±22.36 23.99±16.28 a 25.97±16.86 16.78±14.68 恶心或呕吐 7.51±10.66 5.52±9.92 a 3.53±6.81 2.32±7.68 疼痛 8.17±11.84 17.11±15.69 18.21±15.62 6.40±8.97 气短 13.47±18.13 20.09±21.04 a 19.65±21.11 17.44±18.33 失眠 34.66±27.99 24.06±27.17 a 21.63±22.76 a 24.72±25.29 食欲下降 20.53±21.73 12.14±20.83 a 12.58±20.92 a 12.36±6.40 便秘 15.67±19.17 10.17±17.58 a 13.02±16.26 6.40±14.21 腹泻 10.60±16.50 5.08±14.22 5.86±12.68 7.06±15.63 经济困难 16.11±19.57 13.02±20.29 11.48±17.18 10.60±16.88 注:a表示与131I治疗组比较,差异均有统计学意义(Z=−5.512~−0.984,均P<0.05)。PTC为甲状腺乳头状癌;EORTC QLQ-C30为欧洲癌症研究与治疗组织开发的生存质量核心量表30 表 4 2组PTC患者术前及术后1、3、6个月的EORTC QLQ-C30得分的比较(
±s)$\bar x$ Table 4. EORTC QLQ-C30 scores at preoperative period and at 1, 3 and 6 months after the operation between 131I treatment and non-131I treatment papillary thyroid cacinoma patients (
±s)$\bar x$
131I治疗对早期甲状腺乳头状癌女性患者健康相关生存质量的影响
Impact of 131I treatment on health-related quality of life in female patients with early stage papillary thyroid cancer
-
摘要:
目的 探讨早期甲状腺乳头状癌(PTC)女性患者接受131I治疗与否对健康相关生存质量(HRQOL)的影响。 方法 回顾性分析 2015年 6月至 2016年 6月于吉林大学中日联谊医院接受双侧甲状腺全切的 PTC女性患者 356例(患者组),年龄 21~65(41.00±9.64)岁。应用欧洲癌症研究与治疗组织(EORTC)开发的生存质量核心量表30(QLQ-C30)(简称EORTC QLQ-C30)进行HRQOL评估,分别比较 400名与上述患者年龄相匹配[21~65(41.70±9.38)岁 ]的健康女性体检者(对照组)与患者组在EORTC QLQ-C30各领域得分 [ 包括 5个功能领域、9个症状领域以及独立的总体生活质量(GQOL)]。根据是否接受过131I治疗将所有患者分为 2组:131I 治疗组(205例)和未治疗组(151例),分别比较 2组患者术前及术后 (1、3、6个月)的促甲状腺激素(TSH)和甲状腺球蛋白(Tg)水平、EORTC QLQ-C30各领域得分。数据的组间比较采用 Mann-Whitney U秩和检验。 结果 患者组术前的GQOL得分(59.11±21.12)明显低于对照组(83.08±14.62),除了身体功能以外的其他功能领域的得分均低于对照组,除了疼痛以外的其他症状领域的得分均高于对照组,且差异均有统计学意义(Z=−6.958~−4.673,均 P<0.05)。术后 6个月,患者组的 GQOL得分(73.88±18.04)虽然仍低于对照组,但与术前相比有明显提升,除了身体功能、认知功能、社会功能以外的其他功能领域的得分均比术前升高,除了乏力、疼痛、气短以外的其他症状领域的得分均比术前降低,且差异均有统计学意义(Z=−5.790~−2.876,均 P<0.05)。术前131I治疗组与未治疗组的 GQOL及其他所有领域的得分的差异均无统计学意义(Z=−0.876~−0.001,均 P>0.05)。术后 1个月,131I 治疗组的 TSH和 Tg水平明显高于未治疗组,且差异均有统计学意义(Z=−6.159、−10.061,均 P<0.01);131I治疗组的GQOL得分(50.57±17.72)低于未治疗组(55.74±18.82),功能领域的得分均低于未治疗组,除了疼痛、腹泻、经济困难以外的其他症状领域的得分均高于未治疗组,且差异均有统计学意义(Z=−5.512~−2.550,均 P<0.05)。术后 3个月,131I治疗组的 GQOL得分(64.43±32.12)仍低于未治疗组(72.68±17.29),但131I 治疗组功能领域仅有角色功能、情绪功能、社会功能的得分低于未治疗组,症状领域仅有失眠、食欲下降的得分高于未治疗组,且差异均有统计学意义(Z=−2.939~−0.984,均 P<0.05)。术后 6个月,131I治疗组的 GQOL得分及其他所有领域的得分的差异均无统计学意义(Z=−2.550~−0.008,均 P>0.05)。 结论 131I治疗不影响早期PTC女性患者术后6个月及以后的HRQOL。 -
关键词:
- 碘放射性同位素 /
- 近距离放射疗法 /
- 甲状腺癌,乳头状 /
- 生活质量 /
- EORTC QLQ-C30
Abstract:Objective To analyze the effect of 131I treatment on health-related quality of life (HRQOL) in female patients with early stage thyroid papillary carcinoma (PTC). Methods The data of 356 female PTC patients (aged 21−65 (41.00±9.64) years) with pT1N1aM0 in China-Japan Union Hospital of Jilin University collected from June 2015 to June 2016 were retrospectively analyzed. A total of 400 healthy women (aged 21−65 (41.70±9.38) years) were selected as healthy controls. The HRQOL scores by the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire-core 30(QLQ-C30) between the controls and PTC patients at preoperative period and at 6 months after the operation were compared. Patients were divided into two groups according to whether or not they received 131I treatment (131I treatment group: n=205, non-131I treatment group: n=151). The levels of thyroid-stimulating hormone (TSH), thyroglobulin (Tg), and HRQOL scores at preoperative period and at 1, 3, and 6 months after the operation were compared between the two groups. Informed consent was obtained from all subjects. Non-parametric test of Mann-Whitney U was used to compare the groups with SPSS 19.0 software. Results Before the operation, the global quality of life (GQOL) score of all patients was significantly lower than that of the controls (59.11±21.12 vs. 83.08±14.62), functional domain scores in patients were lower than those in the controls except physical function, symptom domain scores were significantly higher except pain (Z=−6.958 to −4.673, all P<0.05). At 6 months after operation, the GQOL score in patients was still lower than that in the controls (73.88±18.04 vs. 83.08±14.62), but it was significantly higher than the preoperative score. Similar improvements were found in eight other domains other than physical function, cognitive function, social function, fatigue, pain and dyspnoea (Z=−5.790 to −2.876, all P<0.05). No significant difference was found in the preoperative all-domain scores between the 131I and non-131I treatment groups (Z=−0.876 to −0.001, all P>0.05). TSH and Tg in 131I treatment group were significantly higher than non-131I treatment group at 1 month after operation (Z=−6.159, −10.061, both P<0.01). At 1 month after operation, the GQOL score in the 131I treatment group was significantly lower than that in the non-131I treatment group (50.57±17.72 vs. 55.74±18.82). Functional domain scores of the 131I treatment group were significantly lower than those in the non-131I treatment group, symptom domain scores were significantly higher except pain, diarrhea, and financial impact (Z=−5.512 to −2.550, all P<0.05). At 3 months after operation, the GQOL score of the 131I treatment group was still lower than that in the non-131I treatment group (64.43±32.12 vs. 72.68±17.29), but the functional domain scores of the 131I treatment group were lower than that in the non-131I treatment group only in the role function, emotional function, social function, and symptom domain scores were higher only in the insomnia, appetite loss (Z=−2.939 to −0.984, all P<0.05). At 6 months after operation, no difference was found in the GQOL score and any other scores between the 131I treatment group and non-131I treatment group (Z=−2.550 to −0.008, all P>0.05). Conclusion 131I treatment had no impact on HRQOL in female patients with early stage PTC at 6 months after the operation or longer. -
Key words:
- Iodine radioisotopes /
- Brachytherapy /
- Thyroid cancer, papillary /
- Quality of life /
- EORTC QLQ-C30
-
表 1 PTC患者组与对照组的一般资料、TSH和Tg的比较
Table 1. Comparison of general data, thyroid-stimulating hormone and thyroglobulin levels between papillary thyroid cacinoma patients and controls
组别 年龄( ±s,岁)$\bar x $ BMI( ±s,kg/m2)$ \bar x$ TSH[M(P75−P25),mIU/L] Tg[M(P75−P25),ng/mL] 术前 术后6个月 术前 术后6个月 PTC患者组(n=356) 41.00±9.64 26.00±3.91 2.68(1.86) 0.12(0.39) 14.58(27.21) 0.05(0.18) 对照组(n=400) 41.70±9.38 26.46±3.94 1.94(1.81) 1.94(1.81) 16.14(27.02) 16.14(27.02) Z值 −0.510 −0.050 −0.672 −21.33 −0.473 −23.25 P值 0.552 0.938 0.372 <0.01 0.636 <0.01 注:PTC为甲状腺乳头状癌;BMI为体重指数;TSH为促甲状腺激素;Tg为甲状腺球蛋白 表 2 PTC患者组术前、术后6个月与对照组的EORTC QLQ- C30 得分的比较(
±s)$\bar x$ Table 2. EORTC QLQ-C30 scores between papillary thyroid cacinoma patients and controls before the operation and at 6 months after the operation (
±s)$\bar x$ 领域 PTC患者组(n=356) 对照组(n=400) 术前 术后6个月 总体生活质量 59.11±21.12a 73.88±18.04ab 83.08±14.62 功能领域 身体功能 88.91±9.44 89.19±9.25 89.40±9.06 角色功能 80.24±14.07a 82.96±15.14ab 89.58±15.67 情绪功能 74.74±14.55a 78.82±12.88ab 91.42±11.93 认知功能 82.87±15.70a 80.62±16.11a 88.37±14.20 社会功能 85.07±16.41a 83.61±17.08a 91.21±19.14 症状领域 乏力 24.34±21.84a 17.10±15.23a 7.97±10.87 恶心或呕吐 7.30±10.59a 2.29±7.61ab 2.71±6.58 疼痛 8.01±11.81 6.13±8.78 7.33±11.86 气短 13.86±17.88a 16.85±18.10ab 7.75±15.03 失眠 34.64±27.57a 23.69±25.55ab 14.50±19.74 食欲下降 20.41±21.24a 12.45±20.40b 9.58±15.09 便秘 16.01±19.42a 6.65±14.66b 6.33±13.08 腹泻 10.39±16.23a 6.93±15.46b 7.17±13.69 经济困难 15.45±20.34a 11.42±17.86b 11.08±17.22 注:a表示与对照组比较,差异均有统计学意义(Z=−7.806~−2.236,均P<0.05);b表示与术前比较,差异均有统计学意义(Z=−5.790~−2.876,均P<0.05)。PTC为甲状腺乳头状癌;EORTC QLQ-C30为欧洲癌症研究与治疗组织开发的生存质量核心量表30 表 3 2组PTC患者的一般资料、TSH和Tg的比较
Table 3. Comparison of general data, thyroid-stimulating hormone and thyroglobulin levels between 131I treatment and non-131I treatment papillary thyroid cacinoma patients
组别 年龄
( ±s,岁)$\bar x $ BMI
( ±s,kg/m2)$\bar x $ TSH[M(P75−P25),mIU/L] Tg[M(P75−P25),ng/mL] 术前 术后1个月 术后3个月 术后6个月 术前 术后1个月 术后3个月 术后6个月 131I治疗组(n=205) 41.27±9.54 26.48±3.90 2.68(1.74) 107.97(34.50) 0.13(0.27) 0.11(0.35) 13.63(27.19) 1.83(6.17) 0.08(0.24) 0.04(0.18) 未治疗组(n=151) 41.50±9.77 26.47±3.93 2.76(1.92) 0.27(0.84) 0.17(0.43) 0.14(0.13) 18.47(25.14) 0.05(0.17) 0.09(0.27) 0.07(0.18) Z值 −0.172 −0.402 −0.107 −6.159 −1.117 −0.543 −0.662 −10.061 −1.332 −1.117 P值 0.863 0.688 0.903 <0.01 0.264 0.583 0.547 <0.01 0.183 0.325 注:PTC为甲状腺乳头状癌;BMI为体重指数;TSH为促甲状腺激素;Tg为甲状腺球蛋白 表 4 2组PTC患者术前及术后1、3、6个月的EORTC QLQ-C30得分的比较(
±s)$\bar x$ Table 4. EORTC QLQ-C30 scores at preoperative period and at 1, 3 and 6 months after the operation between 131I treatment and non-131I treatment papillary thyroid cacinoma patients (
±s)$\bar x$ 组别 术前 术后1个月 术后3个月 术后6个月 131I治疗组(n=205) 总体生活质量 58.94±21.29 50.57±17.72 64.43±32.12 73.86±18.26 功能领域 身体功能 88.72±9.40 75.42±13.59 87.25±11.04 89.14±9.33 角色功能 80.16±14.14 70.16±23.14 77.32±17.93 82.76±15.12 情绪功能 74.92±14.52 68.94±16.12 73.54±15.57 77.52±13.29 认知功能 82.93±15.38 72.36±18.33 77.56±19.49 81.22±15.99 社会功能 85.61±16.22 73.09±22.89 78.86±21.66 83.90±16.98 症状领域 乏力 23.74±21.48 31.33±19.05 27.53±16.59 17.45±15.64 恶心或呕吐 7.16±10.56 9.43±12.23 2.60±6.95 2.28±7.56 疼痛 7.89±11.82 18.13±16.15 16.91±16.00 5.93±8.63 气短 14.15±17.74 26.01±21.98 21.46±20.69 16.42±17.92 失眠 34.63±27.32 33.33±29.08 29.59±26.79 22.93±25.72 食欲下降 20.32±20.92 18.70±23.80 17.56±22.94 12.52±20.83 便秘 16.26±19.65 22.44±26.66 11.06±19.40 6.83±14.98 腹泻 10.24±16.07 5.69±14.17 6.18±14.15 6.83±15.34 经济困难 14.96±20.92 21.14±25.46 15.61±20.70 12.03±18.52 未治疗组(n=151) 总体生活质量 59.33±20.95 55.74±18.82 a 72.68±17.29 a 73.57±18.01 功能领域 身体功能 89.18±9.51 82.56±15.78 a 88.30±10.55 89.27±9.14 角色功能 80.35±14.02 78.48±19.80 a 81.46±17.32 a 83.56±15.03 情绪功能 74.50±14.63 75.11±15.61 a 79.86±15.36 a 80.08±12.69 认知功能 82.78±15.57 78.92±18.67 a 77.37±19.50 79.80±16.23 社会功能 84.33±16.69 79.58±22.22 a 84.16±17.48 a 83.11±17.15 症状领域 乏力 25.16±22.36 23.99±16.28 a 25.97±16.86 16.78±14.68 恶心或呕吐 7.51±10.66 5.52±9.92 a 3.53±6.81 2.32±7.68 疼痛 8.17±11.84 17.11±15.69 18.21±15.62 6.40±8.97 气短 13.47±18.13 20.09±21.04 a 19.65±21.11 17.44±18.33 失眠 34.66±27.99 24.06±27.17 a 21.63±22.76 a 24.72±25.29 食欲下降 20.53±21.73 12.14±20.83 a 12.58±20.92 a 12.36±6.40 便秘 15.67±19.17 10.17±17.58 a 13.02±16.26 6.40±14.21 腹泻 10.60±16.50 5.08±14.22 5.86±12.68 7.06±15.63 经济困难 16.11±19.57 13.02±20.29 11.48±17.18 10.60±16.88 注:a表示与131I治疗组比较,差异均有统计学意义(Z=−5.512~−0.984,均P<0.05)。PTC为甲状腺乳头状癌;EORTC QLQ-C30为欧洲癌症研究与治疗组织开发的生存质量核心量表30 -
[1] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1−133. DOI: 10.1089/thy.2015.0020. [2] Sterba KR, Zapka J, Cranos C, et al. Quality of life in head and neck cancer patient-caregiver dyads: a systematic review[J]. Cancer Nurs, 2016, 39(3): 238−250. DOI: 10.1097/NCC.0000000000000281. [3] Almeida JP, Vartanian JG, Kowalski LP. Clinical predictors of quality of life in patients with initial differentiated thyroid cancers[J]. Arch Otolaryngol Head Neck Surg, 2009, 135(4): 342−346. DOI: 10.1001/archoto.2009.16. [4] Puxeddu E, Filetti S. The 2009 American Thyroid Association guidelines for management of thyroid nodules and differentiated thyroid cancer: progress on the road from consensus- to evidence-based practice[J]. Thyroid, 2009, 19(11): 1145−1147. DOI: 10.1089/thy.2009.1601. [5] Papadopoulos A, Vrettos I, Kamposioras K, et al. Impact of cancer patients' disease awareness on their family members' health-related quality of life: a cross-sectional survey[J]. Psychooncology, 2011, 20(3): 294−301. DOI: 10.1002/pon.1731. [6] Massolt ET, van der Windt M, Korevaar TIM, et al. Thyroid hormone and its metabolites in relation to quality of life in patients treated for differentiated thyroid cancer[J]. Clin Endocrinol, 2016, 85(5): 781−788. DOI: 10.1111/cen.13101. [7] Hedman C, Djärv T, Strang P, et al. Determinants of long-term quality of life in patients with differentiated thyroid carcinoma—a population-based cohort study in Sweden[J]. Acta Oncol, 2016, 55(3): 365−369. DOI: 10.3109/0284186X.2015.1102965. [8] Nickel B, Tan T, Cvejic E, et al. Health-related quality of life after diagnosis and treatment of differentiated thyroid cancer and association with type of surgical treatment[J]. JAMA Otolaryngol Head Neck Surg, 2019, 145(3): 231−238. DOI: 10.1001/jamaoto.2018.3870. [9] Gamper EM, Wintner LM, Rodrigues M, et al. Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme[J]. Eur J Nucl Med Mol Imaging, 2015, 42(8): 1179−1188. DOI: 10.1007/s00259-015-3022-9. [10] Karapanou O, Papadopoulos A, Vlassopoulou B, et al. Health status of Greek thyroid cancer patients after radioiodine administration compared to a demographically matched general population sample[J]. Hell J Nucl Med, 2012, 15(2): 98−102. DOI: 10.1967/s002449910028. [11] Dagan T, Bedrin L, Horowitz Z, et al. Quality of life of well-differentiated thyroid carcinoma patients[J]. J Laryngol Otol, 2004, 118(7): 537−542. DOI: 10.1258/0022215041615137. [12] Rubic M, Kuna SK, Tesic V, et al. The most common factors influencing on quality of life of thyroid cancer patients after thyroid hormone withdrawal[J]. Psychiatr Danub, 2014, 26 Suppl 3: S520−527. [13] Husson O, Haak HR, Oranje WA, et al. Health-related quality of life among thyroid cancer survivors: a systematic review[J]. Clin Endocrinol, 2011, 75(4): 544−554. DOI: 10.1111/j.1365-2265.2011.04114.x. [14] Tagay S, Herpertz S, Langkafel M, et al. Health-related quality of life, depression and anxiety in thyroid cancer patients[J]. Qual Life Res, 2006, 15(4): 695−703. DOI: 10.1007/s11136-005-3689-7. [15] Duntas LH, Biondi B. Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences[J]. Eur J Endocrinol, 2007, 156(1): 13−19. DOI: 10.1530/eje.1.02310. [16] Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal[J]. J Clin Endocrinol Metab, 2006, 91(3): 878−884. DOI: 10.1210/jc.2005-2064.